Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06629428 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Ublituximab on Motor Functions in Multiple Sclerosis
A Early Phase 1 study of Multiple Sclerosis (MS) - Relapsing-remitting, sponsored by Georgia State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06629428: Recruiting Early Phase 1 study of Multiple Sclerosis (MS) - Relapsing-remitting, sponsored by Georgia State University.
NCT06629428 is a Early Phase 1 study of Multiple Sclerosis (MS) - Relapsing-remitting that is actively recruiting participants, run by Georgia State University. The registered enrollment target is 25 participants, below the 100-participant average among 5 other Multiple Sclerosis (MS) - Relapsing-remitting trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06629428, a Early Phase 1 study of Multiple Sclerosis (MS) - Relapsing-remitting, is actively recruiting participants, sponsored by Georgia State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function, disability status, and cognition will be assessed. Additionally, they will experience large-scale slip perturbations on a treadmill under the protection of a safety harness at the last assessment. The outcome measures will be compared across the assessments to examine the effects of ublituximab on improving their walking function, disability status, cognition, and the responses to the unexpected slip perturbation.
Primary Outcome
The outcome of a slip trial will be deemed a fall if the peak load cell force exceeds 30% of the body weight.
Conditions Studied
Interventions
- DRUG Ublituximab
Study Locations (2)
Georgia
- Georgia State University - Atlanta
- Atlanta Neuroscience Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-11-13 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT06629428 shows while recruiting
NCT06629428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 100-participant average among 5 other Multiple Sclerosis (MS) - Relapsing-remitting trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Multiple Sclerosis (MS) - Relapsing-remitting appearing as the primary indexed condition, and to 1 intervention - of which Ublituximab is the first listed.
NCT06629428 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06629428 about?
NCT06629428 is a clinical study titled "Effects of Ublituximab on Motor Functions in Multiple Sclerosis". The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function...
What is the current status of trial NCT06629428?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2025-11-13. Estimated completion is 2026-12-31.
What conditions does trial NCT06629428 study?
This clinical trial studies the following conditions: Multiple Sclerosis (MS) - Relapsing-remitting.
What interventions are being tested in trial NCT06629428?
The interventions under investigation include: Ublituximab (DRUG).
Who is sponsoring clinical trial NCT06629428?
This trial is sponsored by Georgia State University, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06629428 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (MS) - Relapsing-remitting
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Home Based Functional Balance Intervention for Multiple Sclerosis
RECRUITING · NA
-
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
RECRUITING
-
Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI